Allogene Therapeutics, Inc. (ALLO) compared with its closest peers (CADL, SLDB, FDMT, AURA, TECX). Peer set by Business model: Biotech (Clinical / Commercial-Stage); 10 closest by market cap; US-domiciled. First-party data.
| Company | Market Cap | P/E |
|---|---|---|
| Candel Therapeutics, Inc. (CADL) | $944.24M | -7.8 |
| Solid Biosciences Inc. (SLDB) | $894.91M | -2.8 |
| 4D Molecular Therapeutics, Inc. (FDMT) | $887.29M | -3.1 |
| Aura Biosciences, Inc. (AURA) | $804.23M | -3.1 |
| Tectonic Therapeutic, Inc. (TECX) | $678.35M | -5.1 |
| Prime Medicine, Inc. (PRME) | $583.39M | -2.6 |
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $582.00M | — |
| REGENXBIO Inc. (RGNX) | $571.26M | -3.8 |
| Zura Bio Limited (ZURA) | $545.29M | -4.9 |
| Artiva Biotherapeutics, Inc. (ARTV) | $543.66M | -1.2 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
ALLO overview · ALLO earnings · ALLO financials · ALLO KPIs · ALLO investor relations · ALLO ownership · ALLO filings
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.